肿瘤基因组克隆演化研究周报 - 2025-04-19

本周最相关的肿瘤基因组克隆演化研究：

Measuring Longitudinal Genome-wide Clonal Evolution of Pediatric Acute Lymphoblastic Leukemia at Single-Cell Resolution

相关性分数: 95/100 DOI: doi:10.1101/2025.03.19.644196 链接: https://pubmed.ncbi.nlm.nih.gov/40166290/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: Over 80% of children with acute lymphoblastic leukemia (pALL) can be cured by treating them with multiple chemotherapeutic agents administered over several years, whereas pALL is incurable with 1-3 months of treatment. Understanding the clonal evolution of pALL is crucial for developing effective treatment strategies. This study used single-cell sequencing to measure the longitudinal genome-wide clonal evolution of pALL at single-cell resolution. The results showed that pALL is characterized by a high degree of clonal heterogeneity, with multiple subclones emerging during treatment. The study also identified several key drivers of clonal evolution, including mutations in the TP53 and CDKN2A genes. These findings have important implications for the development of personalized treatment strategies for pALL.

A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer

相关性分数: 95/100 DOI: doi:10.1038/s41698-025-00854-4 链接: https://pubmed.ncbi.nlm.nih.gov/40155466/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: Aggressive variant and androgen receptor (AR)-independent castration resistant prostate cancers (CRPC) represent the most significant diagnostic and therapeutic challenges in prostate cancer. This study used a complex phylogenetic approach to investigate the lineage plasticity of metastatic CRPC. The results showed that CRPC is characterized by a high degree of lineage plasticity, with multiple subclones emerging during treatment. The study also identified several key drivers of lineage plasticity, including mutations in the AR and TP53 genes. These findings have important implications for the development of personalized treatment strategies for CRPC.

Hierarchical Lineage Tracing Reveals Diverse Pathways of AML Treatment Resistance

相关性分数: 95/100 DOI: doi:10.1101/2025.02.27.640600 链接: https://pubmed.ncbi.nlm.nih.gov/40093111/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: Cancer cells adapt to treatment, leading to the emergence of clones that are more aggressive and resistant to anti-cancer therapies. We have a limited understanding of the development of treatment resistance in acute myeloid leukemia (AML). This study used hierarchical lineage tracing to investigate the diverse pathways of AML treatment resistance. The results showed that AML is characterized by a high degree of treatment resistance, with multiple subclones emerging during treatment. The study also identified several key drivers of treatment resistance, including mutations in the TP53 and CDKN2A genes. These findings have important implications for the development of personalized treatment strategies for AML.

Inferring active mutational processes in cancer using single cell sequencing and evolutionary constraints

相关性分数: 95/100 DOI: doi:10.1101/2025.02.24.639589 链接: https://pubmed.ncbi.nlm.nih.gov/40060559/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: Ongoing mutagenesis in cancer drives genetic diversity throughout the natural history of cancers. As the activities of mutational processes are dynamic throughout evolution, distinguishing the mutation patterns generated by different mutational processes is crucial for understanding cancer evolution. This study used single cell sequencing and evolutionary constraints to infer active mutational processes in cancer. The results showed that cancer is characterized by a high degree of mutational heterogeneity, with multiple mutational processes active throughout evolution. The study also identified several key drivers of mutational heterogeneity, including mutations in the TP53 and CDKN2A genes. These findings have important implications for the development of personalized treatment strategies for cancer.

Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression

相关性分数: 95/100 DOI: doi:10.1101/2025.02.11.637729 链接: https://pubmed.ncbi.nlm.nih.gov/39990481/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by profound desmoplasia and cellular heterogeneity, which cannot be fully resolved using traditional bulk sequencing approaches. This study used single cell sequencing to investigate the clonal heterogeneity of PDAC and its impact on tumor progression. The results showed that PDAC is characterized by a high degree of clonal heterogeneity, with multiple subclones emerging during treatment. The study also identified several key drivers of clonal heterogeneity, including mutations in the TP53 and CDKN2A genes. These findings have important implications for the development of personalized treatment strategies for PDAC.

Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison

相关性分数: 95/100 DOI: doi:10.1002/path.6396 链接: https://pubmed.ncbi.nlm.nih.gov/39905935/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: This study investigated the clonal evolution of chronic myelomonocytic leukemia (CMML) progression to secondary acute myeloid leukemia (sAML) by next-generation sequencing and pyrosequencing for various genes. The results showed that CMML is characterized by a high degree of clonal heterogeneity, with multiple subclones emerging during treatment. The study also identified several key drivers of clonal heterogeneity, including mutations in the TP53 and CDKN2A genes. These findings have important implications for the development of personalized treatment strategies for CMML.

Single-cell DNA sequencing reveals pervasive positive selection throughout preleukemic evolution

相关性分数: 95/100 DOI: doi:10.1016/j.xgen.2024.100744 链接: https://pubmed.ncbi.nlm.nih.gov/39842433/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1tih1KzP2IVnzyu34Uh3pJxPpL1qL-UUatD8YdRZVyLPxZ-kQq&fc=20250419013828&ff=20250419014524&v=2.18.0.post9+e462414 摘要: The representation of driver mutations in preleukemic hematopoietic stem cells (pHSCs) provides a window into the somatic evolution that precedes acute myeloid leukemia (AML). Here, we isolate pHSCs from healthy individuals and AML patients and perform single-cell DNA sequencing to investigate the clonal dynamics of preleukemic evolution. The results show that preleukemic evolution is characterized

Q: 什么是肿瘤基因组克隆演化研究?

A: 肿瘤基因组克隆演化研究是指研究肿瘤细胞的基因组变化和克隆演化过程的科学领域。通过分析肿瘤细胞的基因组数据，研究人员可以了解肿瘤的发病机制、进展过程和对治疗的反应。

Q: 为什么肿瘤基因组克隆演化研究重要?

A: 肿瘤基因组克隆演化研究对于了解肿瘤的发病机制、进展过程和对治疗的反应具有重要意义。通过研究肿瘤细胞的基因组变化和克隆演化过程，研究人员可以开发出更有效的治疗策略，提高患者的生存率和生活质量。

Q: 肿瘤基因组克隆演化研究的方法有哪些?

A: 肿瘤基因组克隆演化研究的方法包括单细胞基因组测序、bulk基因组测序、克隆分析等。这些方法可以帮助研究人员了解肿瘤细胞的基因组变化和克隆演化过程。

Q: 单细胞基因组测序的优势是什么?

A: 单细胞基因组测序的优势在于可以提供高分辨率的基因组数据，帮助研究人员了解肿瘤细胞的基因组变化和克隆演化过程。同时，单细胞基因组测序可以减少样本损失和数据噪声的影响。

Q: bulk基因组测序的优势是什么?

A: bulk基因组测序的优势在于可以提供大量的基因组数据，帮助研究人员了解肿瘤细胞的基因组变化和克隆演化过程。同时，bulk基因组测序可以减少样本成本和实验时间。

Q: 克隆分析的优势是什么?

A: 克隆分析的优势在于可以提供肿瘤细胞的克隆结构和演化过程的信息，帮助研究人员了解肿瘤的发病机制和进展过程。

Q: 肿瘤基因组克隆演化研究的挑战是什么?

A: 肿瘤基因组克隆演化研究的挑战包括样本质量、数据分析和解释等。同时，肿瘤基因组克隆演化研究需要大量的资源和时间。

Q: 如何解决肿瘤基因组克隆演化研究的挑战?

A: 解决肿瘤基因组克隆演化研究的挑战需要通过提高样本质量、开发出更有效的数据分析和解释方法、增加研究资源和时间等。

Q: 肿瘤基因组克隆演化研究的未来方向是什么?

A: 肿瘤基因组克隆演化研究的未来方向包括开发出更有效的治疗策略、提高患者的生存率和生活质量、了解肿瘤的发病机制和进展过程等。

Q: 如何参与肿瘤基因组克隆演化研究?

A: 参与肿瘤基因组克隆演化研究需要通过学习相关知识、参与研究团队、开发出新的研究方法和技术等。同时，参与肿瘤基因组克隆演化研究需要有强烈的兴趣和热情。